Skip to main content
. 2021 Apr 15;11:8203. doi: 10.1038/s41598-021-87684-z

Table 1.

Baseline characteristics of peritoneal dialysis patients stratified by kidney size (n = 83).

Variable All patients (n = 83) Diabetic patients with enlarged or normal kidney size (n = 67) Diabetic patients with small kidney size (n = 16) P value
Demographics
Age, years 69.70 ± 11.57 68.03 ± 11.26 76.63 ± 10.63 0.007**
Female sex, n (%) 40 (48.2) 28 (41.8) 12 (75.0) 0.017*
Biopsy-proved glomerulonephritis, n (%) 1 (1.2) 1 (1.5) 0 (0.0) 1.000
Polycystic kidney disease, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Hypertension, n (%) 75 (90.4) 61 (91.0) 14 (87.5) 0.666
Cardiovascular disease, n (%) 34 (41.0) 26 (38.8) 8 (50.0) 0.413
Chronic liver disease, n (%) 5 (6.0) 3 (4.5) 2 (12.5) 0.226
Hepatitis B virus carrier, n (%) 10 (12) 9 (13.4) 1 (6.3) 0.428
Hepatitis C virus carrier, n (%) 6 (7.2) 5 (7.5) 1 (6.3) 0.866
Body mass index, kg/m2 25.47 ± 3.71 25.77 ± 3.59 24.29 ± 4.09 0.154
Smoking habit, n (%) 15 (18.1) 13 (19.4) 2 (12.5) 0.519
Alcohol consumption, n (%) 7 (8.4) 6 (9.0) 1 (6.3) 0.726
Immunosuppressive medications 0 (0) 0 (0) 0 (0) 1.000
Duration of peritoneal dialysis, month 42.82 ± 3.72 39.16 ± 32.22 59.14 ± 35.33 0.701
Duration of diabetes mellitus, month 174.69 ± 1158.67 151.44 ± 85.31 272.09 ± 305.09 0.006**
Hypoglycemic therapy 0.455
Oral hypoglycemic agents, n (%) 59 (71.1) 47 (70.1) 12 (75.0)
Insulin, n (%) 18 (21.7) 16 (23.9) 2 (12.5)
Oral hypoglycemic agents and insulin, n (%) 6 (0.72) 4 (0.60) 2 (12.5)

*P < 0.05; **P < 0.01.